The trial found that after 5 years, Wegovy significantly reduced the risk of death from heart disease by 15% and reduced the risk of cardiovascular events including nonfatal heart attacks and strokes by 20%, compared to an inactive placebo
Clinical trials are being run on combination therapies that can help preserve muscle massa big issue for GLP-1 usersand maybe even cut back on GI symptoms
224 Although, there is evidence to suggest that islet alpha-cells can secrete GLP-1 during healthy circumstances and that this secretion becomes elevated during diabetic/disease conditions, whether these cells secrete GLP-1 and the physiological relevance of this remains unclear
Intravenous infusion of GLP-1 for 48 h in healthy human subjects increased muscle sympathetic nerve activity but had no effect on BP, norepinephrine plasma concentration, or the sympathetic/parasympathetic balance as estimated by the HR variability, suggesting that the increase in sympathetic drive is at least partially compensated by an increase in the parasympathetic activity [53]
R., Andersen, A
Hey, you have to show the VCs you are worthy of unicorn valuation
